Indication*

(Intravenous) Metastatic Breast Cancer. Locally advanced Bladder Cancer, Metastatic Bladder Cancer, Locally advanced Ovarian Cancer, Metastatic Ovarian Cancer, Locally advanced Non-small Cell Lung Carcinoma, Metastatic Non-small Cell Lung Carcinoma, Locally advanced Adenocarcinoma of Pancreas, Metastatic Adenocarcinoma of Pancreas.

Directions for Use*

(Metastatic Breast Cancer) Adult: In patients with unresectable, locally recurrent cases who have relapsed following adjuvant/neoadjuvant chemotherapy: In combination with paclitaxel: 1,250 mg/m2 via infusion over 30 minutes on days 1 and 8 of a 21-days cycle. Dose may be reduced with each cycle or within a cycle based on toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy. (locally advanced Bladder Cancer, Metastatic Bladder Cancer) Adult: In combination with cisplatin: 1,000 mg/m2 via infusion over 30 minutes on days 1 , 8, and 15 of each 28-day cycle, followed by a 1-week rest period. This 4-week cycle is hen repeated. Dose may be reduced with each cycle or within a cycle based on the amount of toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines). (locally advanced ovarian cancer, metastatic ovarian cancer) Adult: In cases that have relapsed at least 6 months after completion of platinum-based therapy: In combination with carboplatin:1,000 mg/m2 via infusion over 30 minutes on days 1 and 8 of each 21-day cycle. dose may be reduced with each cycle or within a cycle based on toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy. (locally advanced non-small cell lung carcinoma, metastatic non-small cell lung carcinoma) Adult: As monotherapy: 1,000 mg/m2 once weekly via infusion over 30 minutes for 3 weeks followed by a 1-week rest period. This 4-week cycle is then repeated. In combination with cisplatin: 1,2250 mg/m2 via infusion over 30 minutes on days 1 and 8 each 21-day cycle, followed by a 1-week rest period. This 3-week cycle is then repeated. Alternatively, 1,000 mg/m2 via infusion over 30 minutes on days 1, 8, and 15 of each 28-day cycle, followed by a 1 week rest period. this 4-week cycle is then repeated. Dose may be reduced with each cycle or within a cycle based on toxicity. Patient should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy. (locally advanced adenocarcinoma of pancreas, metastatic adenocarcinoma of pancreas) Adult: 1,000 mg/m2 once weekly via infusion over 30 minutes for 7 weeks, followed by a 1 week rest period. Subsequent cycles; 1,000 mg/m2 once weekly for 3 consecutive weeks out of every 4 weeks. Alternatively, 1,000 mg/m2 on days 1 ,8 25 of each 28-day cycle. Dose may be reduced with each cycle or within a cycle based on toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy. Treatment recommendations may vary among countries (refer to specific local guidelines).

Administration*

*written indications, directions, and administration are updated as of March 10, 2024 and may not be accurate with the actual product purchased. Please read the details in the packaging.

Share

Share

Link

Close share Copy link

View full details